Every 424B that BIOATLA INC (BCAB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BCAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAB filings page.
BioAtla is registering 842,440 shares of common stock to be issued to YA II PN, Ltd. pursuant to its Standby Equity Purchase Agreement dated November 20, 2025. The shares are priced at approximately $0.179 per share for total proceeds of approximately $151,000, which the company intends to use for working capital and general corporate purposes. The company expects to issue the shares on or about March 20, 2026. This prospectus supplement also covers the resale of these shares by YA II PN, Ltd. to the public.
Common stock outstanding after the offering will be 82,846,317 shares. The resale and methods of sale are described in the referenced "Plan of Distribution."
BioAtla is offering 631,163 shares of common stock to YA II PN, Ltd. (Yorkville) at approximately $0.171 per share pursuant to a Standby Equity Purchase Agreement dated November 20, 2025. The total purchase price is approximately $108,000 and the company expects to issue the shares on or about March 13, 2026. This prospectus supplement also covers the resale of those shares by Yorkville to the public. Common stock outstanding after the issuance will be 81,801,593 shares. The company states it intends to use net proceeds for working capital and other general corporate purposes.
BioAtla is issuing 931,032 shares of common stock to YA II PN, Ltd. under a Standby Equity Purchase Agreement dated November 20, 2025, at approximately $0.166 per share for total gross proceeds of approximately $154,000. The company expects to issue the shares on or about March 9, 2026.
The prospectus supplement also covers the resale of these shares by YA II PN, Ltd. to the public. Common stock outstanding after the issuance would be 81,170,430 shares.
BioAtla, Inc. is registering up to $22.5 million of common stock plus 243,428 shares of common stock in connection with new financing arrangements. The company has already received $7.5 million of pre-paid advances from three investors, to be repaid in stock at prices tied to the market but not below $0.23 per share, with interest at 4% annually, rising to 18% on default. A separate standby equity purchase agreement lets BioAtla sell up to $15 million of additional shares to Yorkville over 36 months at 97% of market price, subject to a 4.99% ownership cap. Yorkville also receives the 243,428 commitment shares as a 2.00% fee. These structures provide flexible access to capital but could significantly dilute existing shareholders as shares are issued.
BioAtla remains a clinical-stage oncology company, reporting $8.3 million in cash as of September 30 2025, a new $2 million milestone payment from Context Therapeutics, and recent FDA alignment on a planned Phase 3 ozuriftamab vedotin trial.